Reference health

A New Daunomycin–Peptide Conjugate: Synthesis, Characterization and the Effect on the Protein Expression Profile of HL-60 Cells <i>in Vitro</i>

https://doi.org/10.1021/bc2004236
CiteStamped reference-health badge
41/41 checkable references clean · checked 2026-07-23

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

9 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 41 checked references that resolve
resolves10.1016/0002-9343(77)90315-1
Daunomycin-induced cardiotoxicity in children and adults
resolves10.1097/00029330-200803010-00019
Comparative proteomic analysis of differentially expressed proteins between K562 and K562/ADM cells
resolves10.1002/pmic.200800633
Proteomic analysis of multidrug‐resistance mechanisms in adriamycin‐resistant variants of DLKP, a squamous lung cancer cell line
resolves10.2119/molmed.2008.00129
Comparative Mitochondrial Proteomic Analysis of Raji Cells Exposed to Adriamycin
resolves10.1016/j.freeradbiomed.2006.08.006
Redox proteomic identification of oxidized cardiac proteins in Adriamycin-treated mice
resolves10.1002/1615-9861(200206)2:6<697::AID-PROT697>3.0.CO;2-F
Monitoring daunorubicin-induced alterations in protein expression in pancreas carcinoma cells by two-dimensional gel electrophoresis
resolves10.1002/pmic.200800626
Proteomic analysis of doxorubicin‐induced changes in the proteome of HepG2cells combining 2‐D DIGE and LC‐MS/MS approaches
resolves10.1016/S0959-8049(97)00338-9
Low toxicity and high antitumour activity of Daunomycin by conjugation to an immunopotential amphoteric branched polypeptide
resolves10.1016/j.bbamem.2010.07.023
Daunomycin-polypeptide conjugates with antitumor activity
resolves10.1016/S0960-894X(99)00678-2
Structure–activity relationships of carboxymethylpullulan-peptide-doxorubicin conjugates—systematic modification of peptide spacers
resolves10.1158/1078-0432.CCR-03-0544
Design of a pH-Sensitive Polymeric Carrier for Drug Release and Its Application in Cancer Therapy
resolves10.1002/bip.360220168
Specific and nonspecific macromolecule–drug conjugates for the improvement of cancer chemotherapy
resolves10.1016/S0304-3835(77)96407-2
Steric influence of the orientation of the primary amino group at position 3 of the sugar moiety of anthracycline antibiotics in DNA binding properties
resolves10.1021/jm001065f
Novel Peptide Conjugates for Tumor-Specific Chemotherapy
resolves10.1016/j.bmc.2006.02.007
Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity
resolves10.1021/jm00278a032
Antitumor activity of some derivatives of daunorubicin at the amino and methyl ketone functions
resolves10.1007/s11095-007-9303-7
Cell Penetrating Peptides: Intracellular Pathways and Pharmaceutical Perspectives
resolves10.1016/S0960-894X(01)00223-2
A New Method for Chemoselective Conjugation of Unprotected Peptides to Dauno- and Doxorubicin
resolves10.1016/j.bmc.2005.02.040
Improved synthesis of daunomycin conjugates with triplex-forming oligonucleotides. The polypurine tract of HIV-1 as a target
resolves10.1021/jm0606591
Improved Therapeutic Efficacy of Doxorubicin through Conjugation with a Novel Peptide Drug Delivery Technology (Vectocell)
resolves10.3998/ark.5550190.0009.313
Synthesis of daunomycin-oligoarginine conjugates and their effect on human leukemia cells (HL-60)
resolves10.1124/mol.57.4.679
New Advances in the Transport of Doxorubicin through the Blood-Brain Barrier by a Peptide Vector-Mediated Strategy
resolves10.2174/092986708785909157
New Derivatives of GnRH as Potential Anticancer Therapeutic Agents
resolves10.1002/bip.21264
New daunomycin–oligoarginine conjugates: Synthesis, characterization, and effect on human leukemia and human hepatoma cells
resolves10.2174/157016110791112241
ErbB Targeted Drugs and Angiogenesis
resolves10.1016/j.ceb.2008.12.010
ErbB receptors and signaling pathways in cancer
resolves10.1016/j.drup.2003.11.002
Selective targeting of cancer cells using synthetic peptides
resolves10.1007/0-306-46817-4_16
Development of Clinical Trial of E1A Gene Therapy Targeting HER-2/neu-overexpressing Breast and Ovarian Cancer
resolves10.1016/S1368-7646(03)00024-4
The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery
resolves10.1016/S0065-230X(08)60784-8
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
resolves10.1096/fj.02-0280fje
Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells
resolves10.1158/0008-5472.CAN-06-2480
A Peptide Conjugate of Vitamin E Succinate Targets Breast Cancer Cells with High ErbB2 Expression
resolves10.1016/j.ejpb.2004.03.031
Drug delivery of oligonucleotides by peptides
resolves10.1093/jnci/djq315
Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells
resolves10.1002/ijc.24580
Increased expression of ErbB‐2 in liver is associated with hepatitis B × antigen and shorter survival in patients with liver cancer
resolves10.1021/bi00260a005
Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on the interaction of daunomycin with deoxyribonucleic acid
resolves10.1016/0022-2836(74)90031-X
Theoretical aspects of DNA-protein interactions: Co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice
resolves10.1038/270347a0
Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture
resolves10.1016/0006-3002(63)90513-4
Studies on succinate-tetrazolium reductase systems
resolves10.1529/biophysj.107.116921
Peptide Sequence and Conformation Strongly Influence Tryptophan Fluorescence
resolves10.1016/j.bbrc.2010.01.055
The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U-937) cells
The 9 references without a DOI — listed, not checked
no DOI — not checkedref1/cit1
no DOI — not checkedCancer Management: A Multidisciplinary Approach
no DOI — not checkedref4/cit4
no DOI — not checkedref7/cit7
no DOI — not checkedref10/cit10
no DOI — not checkedref15/cit15
no DOI — not checkedref17/cit17
no DOI — not checkedref29/cit29
no DOI — not checkedref44/cit44
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1021/bc2004236"><img src="https://citestamp.com/citestamped/10.1021/bc2004236/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1021/bc2004236/badge.svg)](https://citestamp.com/citestamped/10.1021/bc2004236)